https://rijournals.com/biological-and-applied-science/

RESEARCH INVENTION JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES 6(1):38-42, 2026

©RIJBAS Publications ISSN: 1597-2879

https://doi.org/10.59298/RIJBAS/2026/613842

Hepatic Glucokinase Activators versus Sulfonylureas: Hypoglycemia Risk Reduction in Type 2 Diabetes Management

Mpora Kakwanzi Evelyn

Department of Pharmacognosy Kampala International University Uganda
Email: evelyne.mpora@studwc.kiu.ac.ug

ABSTRACT

Type 2 diabetes mellitus (T2DM) was characterized by impaired glucose homeostasis and insulin resistance, necessitating pharmacologic interventions to maintain glycemic control. Sulfonylureas (SUs) had been widely used to stimulate insulin secretion but were associated with a significant risk of hypoglycemia. Hepatic glucokinase activators (GKAs) are emerging agents that enhance hepatic glucose uptake and metabolism, potentially reducing hypoglycemia risk by acting insulin-independently. This review critically examined the comparative hypoglycemia risk profiles of hepatic glucokinase activators versus sulfonylureas in T2DM management. A comprehensive literature search was conducted using major scientific databases to identify preclinical and clinical studies evaluating hypoglycemia incidence associated with GKAs and SUs, focusing on randomized controlled trials, mechanistic studies, and meta-analyses. Sulfonylureas induce hypoglycemia predominantly by stimulating pancreatic β-cell insulin secretion regardless of ambient glucose levels. In contrast, hepatic GKAs amplify glucose phosphorylation in hepatocytes, enhancing glycogen synthesis and glucose clearance without direct insulin stimulation. Clinical evidence indicated that GKAs reduced fasting and postprandial glucose effectively with a lower incidence of hypoglycemia compared to SUs. Nevertheless, hepatic GKAs' efficacy varied depending on their isoform selectivity and pharmacokinetic profiles. Limitations included the relatively recent clinical trial data on GKAs and the long-term safety concerns related to liver metabolism modulation. Hepatic glucokinase activators represented a promising therapeutic alternative to sulfonylureas, with a more favorable hypoglycemia risk profile in the management of T2DM. However, further longitudinal studies were required to establish sustained efficacy, safety, and optimal dosing.

Keywords: Type 2 diabetes mellitus, Hepatic glucokinase activators, Sulfonylureas, hypoglycemia, Glucose metabolism, Pancreatic β-cell.

INTRODUCTION

Type 2 diabetes mellitus is a chronic metabolic disorder defined by insulin resistance coupled with progressive β-cell dysfunction, leading to persistent hyperglycemia [1–3]. Central to maintaining glucose homeostasis is the hepatic enzyme glucokinase, which catalyzes the phosphorylation of glucose to glucose-6-phosphate, a key step in glycolysis and glycogen synthesis. Glucokinase's unique kinetic properties allow it to act as a glucose sensor in hepatocytes, regulating glucose uptake in response to fluctuating plasma glucose levels [4].

Historically, sulfonylureas have formed a core component of T2DM pharmacotherapy by binding to ATP-sensitive potassium channels on pancreatic β-cells, augmenting insulin release independently of glucose concentration [5]. Despite their efficacy in lowering blood glucose, SUs are frequently associated with hypoglycemic episodes, including severe events requiring medical intervention. Hypoglycemia represents a crucial clinical limitation, influencing drug choice and patient outcomes.

This review aims to critically synthesize evidence comparing the hypoglycemia risk profiles of hepatic glucokinase activators versus sulfonylureas in the treatment of T2DM, focusing on their mechanisms of action, clinical efficacy, safety, and implications for therapeutic decision-making.

Molecular Mechanisms of Hepatic Glucokinase Activation and Sulfonylurea Action

Understanding the distinct biochemical pathways through which hepatic GKAs and sulfonylureas affect glucose metabolism elucidates their differential hypoglycemia risk profiles. Hepatic glucokinase, a hexokinase isoform expressed predominantly in the liver, facilitates the phosphorylation of glucose with low affinity but high capacity, enabling fine-tuned control of postprandial glucose disposal [6, 7]. Activation of glucokinase via allosteric GKAs increases the enzyme's affinity for glucose, thereby accelerating hepatic glucose uptake and glycogen synthesis. This mechanism reduces plasma glucose concentrations without directly triggering insulin secretion, lessening the potential for hypoglycemia.

In contrast, sulfonylureas target the pancreatic β-cell K_ATP channel subunits, leading to cell depolarization, calcium influx, and insulin exocytosis regardless of ambient glucose levels [8]. This glucose-independent insulin release can provoke hypoglycemic events, especially under fasting conditions or overdose. The sustained stimulation can eventually exhaust β-cell function.

Mechanistic studies indicate that hepatic GKAs provide glucose-lowering effects by augmenting first-pass clearance and glycogenesis, mechanisms that maintain glucose regulation within physiological limits. However, some GKAs demonstrate partial pancreatic effects, complicating the risk assessment. These findings underscore the importance of isoform selectivity in minimizing adverse events.

Glucokinase activation in the liver modulates glucose metabolism more precisely than sulfonylurea-mediated insulin secretion, offering a biochemical basis for lower hypoglycemia risk [9, 10]. This distinction frames the clinical comparison of these agents.

Analytical and Experimental Methods in Hypoglycemia Risk Assessment

The evaluation of hypoglycemia associated with glucose-lowering agents requires rigorous analytical and clinical methodologies to capture incidence, severity, and biochemical correlates. Studies assessing sulfonylureas and hepatic GKAs employ a variety of experimental designs, including randomized controlled trials (RCTs), crossover studies, and prospective cohort analyses. Continuous glucose monitoring (CGM) and standardized biochemical assays facilitate real-time detection of hypoglycemic episodes, while standardized definitions of hypoglycemia (e.g., plasma glucose <70 mg/dL) ensure consistency across studies [11].

RCTs investigating sulfonylureas frequently report higher rates of hypoglycemia compared to other drugs, reinforced by meta-analytic data stratified by drug subclass and dosing regimens. For hepatic GKAs, early phase clinical trials incorporate pharmacodynamic endpoints such as hepatic glucose uptake, fasting glucose reduction, and postprandial glucose excursions alongside safety assessments, including hypoglycemia monitoring. However, the heterogeneity in GKA molecular structures and their pharmacokinetics challenges direct comparison across trials.

Additionally, experimental animal models provide mechanistic insights but yield limited translational precision owing to interspecies metabolic differences. Advanced imaging and tracer studies elucidate hepatic glucose flux enhanced by GKAs, supporting clinical findings [12]. Analytical methods underscore the need for precise glucose monitoring and standardized reporting to accurately reflect hypoglycemia risk. Analytical rigor and evolving methodologies strengthen the comparative safety assessments but require further harmonization to refine clinical guidelines. This methodological underpinning leads to examination of clinical outcomes and implications.

Clinical and Pathophysiological Implications of Hypoglycemia in T2DM Therapy

Hypoglycemia remains one of the most formidable complications hindering optimal glycemic control in T2DM therapy [13, 14]. Beyond acute neuroglycopenic symptoms, repeated hypoglycemic episodes adversely affect cardiovascular health, cognitive function, and overall quality of life. The hypoglycemia risk intrinsic to sulfonylurea use often necessitates dose adjustments or drug discontinuation, compromising glycemic targets and increasing the burden of diabetes complications.

Clinical evidence consistently demonstrates that SUs, while efficacious at reducing glycemic indices, elevate hypoglycemia incidence compared to many other glucose-lowering agents [15]. This effect is exacerbated in elderly patients, those with renal impairment, or concomitant polypharmacy. In contrast, hepatic glucokinase activators show promising clinical profiles marked by reduced hypoglycemic episodes, attributable to their glucose-dependent mechanism of action. Early clinical trials reveal improvements in fasting and postprandial glucose without increasing severe hypoglycemia.

However, the liver-centric targeting of GKAs also raises pathophysiological questions regarding effects on hepatic lipid metabolism and potential induction of steatosis or dyslipidemia [16]. Balancing glycemic benefits against these risks requires a nuanced understanding. The pathophysiological context suggests that GKAs might better preserve β-cell function by circumventing excessive insulin secretagogue demand. Overall, hypoglycemia risk differences between GKAs and SUs impact therapeutic strategies and patient safety, emphasizing the need for tailored pharmacotherapy in T2DM management.

Therapeutic and Translational Perspectives

The translational potential of hepatic GKAs lies in their novel mode of action that complements existing therapies [17]. As add-on agents or monotherapies, GKAs offer a strategic alternative to sulfonylureas, particularly in patients at high risk for hypoglycemia or with contraindications to insulin secretagogues. Pharmacokinetic variability among GKAs necessitates individualized dosing regimens to optimize efficacy while mitigating hepatic side effects.

Recent phase II and III trial data suggest that GKAs improve glycemic control with fewer hypoglycemic events compared to traditional sulfonylureas [12, 18]. However, some agents have demonstrated transient elevations in liver enzymes and modest increases in triglyceride levels, necessitating ongoing safety monitoring. Additionally, combinational therapy with metformin or sodium-glucose cotransporter 2 inhibitors requires further investigation to define synergistic effects and cumulative risks.

Commercial development pipelines incorporate next-generation GKAs with improved hepatic specificity and metabolic profiles, reflecting advances in medicinal chemistry. Translational research aims to integrate biomarker-driven patient stratification to maximize benefit-to-risk ratios. Despite these advances, limitations remain, including long-term safety data scarcity and an incomplete understanding of GKA's impact on hepatic energy homeostasis and lipid storage [19, 20].

The therapeutic promise of GKAs highlights the potential paradigm shift toward liver-targeted glucose control, underpinning future clinical management frameworks.

Gaps, Controversies, and Future Research Directions

While evidence increasingly supports the hypoglycemia safety advantage of hepatic GKAs over sulfonylureas, significant knowledge gaps and controversies persist. The long-term metabolic and hepatic consequences of sustained glucokinase activation remain incompletely defined, particularly regarding steatosis risk and possible fibrotic progression [21, 22]. The heterogeneity of GKA compounds, varying in isoform selectivity and bioavailability, complicates data interpretation and cross-trial comparisons.

Controversy exists around whether mild pancreatic effects observed with some GKAs pose unforeseen hypoglycemia risks or diminish long-term β-cell preservation [23]. Moreover, the relative influence of hepatic versus pancreatic glucokinase in glucose homeostasis and its modulation by pharmacologic activators requires further delineation. Another unresolved issue lies in how GKAs integrate with emerging T2DM treatments and whether combination therapies exacerbate or mitigate hypoglycemia [24].

Future research must focus on large-scale, long-duration randomized studies to assess chronic safety, elucidate mechanistic pathways of hepatic glucose metabolism modulation, and explore personalized medicine approaches using genetic and metabolic biomarkers [25]. Additionally, standardization of hypoglycemia definitions and monitoring protocols will enhance evidence robustness. Addressing these gaps will critically inform clinical guidelines and drug development strategies.

Thus, the evolving field of hepatic glucokinase activation offers promising therapeutic innovation, contingent upon rigorous investigation into safety and efficacy.

CONCLUSION

This review synthesizes current understanding of the comparative hypoglycemia risks of hepatic glucokinase activators and sulfonylureas in T2DM management. Mechanistically, hepatic GKAs reduce plasma glucose by enhancing hepatic glucose phosphorylation and glycogen synthesis without stimulating insulin release, which markedly decreases hypoglycemia incidence compared to sulfonylureas' direct β-cell insulinotropic action. Clinical trials corroborate these biochemical distinctions with consistent reports of fewer hypoglycemic events in patients treated with GKAs. Nevertheless, the evidence is tempered by the relatively recent introduction of GKAs, limited long-term safety data, and concerns regarding hepatic lipid metabolism and enzyme elevations. Sulfonylureas retain utility owing to established efficacy and cost-effectiveness but show a higher propensity for hypoglycemia, particularly in vulnerable populations. The balance of current evidence favors hepatic GKAs as a safer alternative for hypoglycemia, positioning them as a significant advancement in T2DM therapeutics. However, a comprehensive understanding of their long-term metabolic effects and optimization of treatment regimens remain critical for widespread clinical adoption. Continued rigorous investigation will help define the ultimate place of GKAs in diabetes care algorithms. Extensive longitudinal clinical trials assessing the long-term safety and metabolic impact of hepatic glucokinase activators are recommended before broader clinical integration.

REFERENCES

1. Uti, D.E., Atangwho, I.J., Alum, E.U., Egba, S.I., Ugwu, O.P.-C., Ikechukwu, G.C.: Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. Natural Product Communications. 20, 1934578X251323393 (2025). https://doi.org/10.1177/1934578X251323393
2. Erisa, K., Raphael, I., Emmanuel I., O., Michael B, O., Subbarayan, S. V.: Exploring Indigenous Medicinal Plants for Managing Diabetes Mellitus in Uganda: Ethnobotanical Insights, Pharmacotherapeutic Strategies, and

National Development Alignment. INOSR ES. 12, 214–224 (2023). https://doi.org/10.59298/INOSRES/2023/2.17.1000

3. Hudish, L.I., Reusch, J.E.B., Sussel, L.: β Cell dysfunction during progression of metabolic syndrome to type 2 diabetes. J Clin Invest. 129, 4001–4008 (2019). https://doi.org/10.1172/JCI129188
4. McKerrecher, D., Waring, M.J.: Property-Based Design in the Optimisation of Benzamide Glucokinase Activators. In: Progress in Medicinal Chemistry. pp. 1–43. Elsevier (2013)
5. Li, X.-T., Yun, M.-Z.: The impact of sulfonylureas on diverse ion channels: an alternative explanation for the antidiabetic actions. Front. Cell Dev. Biol. 13, (2025). https://doi.org/10.3389/fcell.2025.1528369
6. Kajani, S., Laker, R.C., Ratkova, E., Will, S., Rhodes, C.J.: Hepatic glucagon action: beyond glucose mobilization. Physiological Reviews. 104, 1021–1060 (2024). https://doi.org/10.1152/physrev.00028.2023
7. Agius, L.: Targeting Hepatic Glucokinase in Type 2 Diabetes. Diabetes. 58, 18–20 (2009). https://doi.org/10.2337/db08-1470
8. Li, X.-T., Yun, M.-Z.: The impact of sulfonylureas on diverse ion channels: an alternative explanation for the antidiabetic actions. Front. Cell Dev. Biol. 13, (2025). https://doi.org/10.3389/fcell.2025.1528369
9. Chang, N.: Syntaxin-1A Inhibits the KATP Channel Through Interaction with Distinct Sites Along the Nucleotide-binding Folds of Sulfonylurea Receptor 1. (2010)
10. Abu Aqel, Y., Alnesf, A., Aigha, I.I., Islam, Z., Kolatkar, P.R., Teo, A., Abdelalim, E.M.: Glucokinase (GCK) in diabetes: from molecular mechanisms to disease pathogenesis. Cell Mol Biol Lett. 29, 120 (2024). https://doi.org/10.1186/s11658-024-00640-3
11. Alum, E.U.: Optimizing patient education for sustainable self-management in type 2 diabetes. Discov Public Health. 22, 44 (2025). https://doi.org/10.1186/s12982-025-00445-5
12. Matschinsky, F.M.: GKAs for diabetes therapy: why no clinically useful drug after two decades of trying? Trends in Pharmacological Sciences. 34, 90–99 (2013). https://doi.org/10.1016/j.tips.2012.11.007
13. Adolfsson, P., Rentoul, D., Klinkenbijl, B., Parkin, C.G.: Hypoglycaemia Remains the Key Obstacle to Optimal Glycaemic Control – Continuous Glucose Monitoring is the Solution. Eur Endocrinol. 14, 50–56 (2018). https://doi.org/10.17925/EE.2018.14.2.50
14. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obesity Medicine. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
15. Kalra, S., Bahendeka, S., Sahay, R., Ghosh, S., Md, F., Orabi, A., Ramaiya, K., Al Shammari, S., Shrestha, D., Shaikh, K., Abhayaratna, S., Shrestha, P.K., Mahalingam, A., Askheta, M., A. Rahim, A.A., Eliana, F., Shrestha, H.K., Chaudhary, S., Ngugi, N., Mbanya, J.C., Aye, T.T., Latt, T.S., Akanov, Z.A., Syed, A.R., Tandon, N., Unnikrishnan, A.G., Madhu, S.V., Jawa, A., Chowdhury, S., Bajaj, S., Das, A.K.: Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus – International Task Force. Indian J Endocrinol Metab. 22, 132–157 (2018). https://doi.org/10.4103/ijem.IJEM_556_17
16. Zhang, Z., Ji, G., Li, M.: Glucokinase regulatory protein: a balancing act between glucose and lipid metabolism in NAFLD. Front Endocrinol (Lausanne). 14, 1247611 (2023). https://doi.org/10.3389/fendo.2023.1247611
17. Hale, C., Lloyd, D.J., Pellacani, A., Véniant, M.M.: Molecular targeting of the GK-GKRP pathway in diabetes. Expert Opinion on Therapeutic Targets. 19, 129–139 (2015). https://doi.org/10.1517/14728222.2014.965681
18. Li, W., Zhang, X., Sun, Y., Liu, Z.: Recent clinical advances of glucokinase activators in the treatment of diabetes mellitus type 2. Die Pharmazie - An International Journal of Pharmaceutical Sciences. 75, 230–235 (2020). https://doi.org/10.1691/ph.2020.0409
19. Li, C., Zhang, Y., Chen, L., Li, X.: Glucokinase and glucokinase activator. Life Metabolism. 2, load031 (2023). https://doi.org/10.1093/lifemeta/load031
20. Ikpozu, E.N., Offor, C.E., Igwenyi, I.O., Obaroh, I.O., Ibiam, U.A., Ukaidi, C.U.A.: RNA-based diagnostic innovations: A new frontier in diabetes diagnosis and management. Diabetes & Vascular Disease Research. 22, 14791641251334726 (2025). https://doi.org/10.1177/14791641251334726
21. Zhang, Z., Ji, G., Li, M.: Glucokinase regulatory protein: a balancing act between glucose and lipid metabolism in NAFLD. Front Endocrinol (Lausanne). 14, 1247611 (2023). https://doi.org/10.3389/fendo.2023.1247611
22. Truong, X.T., Lee, D.H.: Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications. Diabetes Metab J. 49, 964–986 (2025). https://doi.org/10.4093/dmj.2025.0644
23. Oberhauser, L., Maechler, P.: Lipid-Induced Adaptations of the Pancreatic Beta-Cell to Glucotoxic Conditions Sustain Insulin Secretion. IJMS. 23, 324 (2021). https://doi.org/10.3390/ijms23010324
24. Haddad, D., Dsouza, V.S., Al-Mulla, F., Al Madhoun, A.: New-Generation Glucokinase Activators: Potential Game-Changers in Type 2 Diabetes Treatment. International Journal of Molecular Sciences. 25, 571 (2024). https://doi.org/10.3390/ijms25010571

https://rijournals.com/biological-and-applied-science/

25. Zhang, H., Wang, K., Zhao, H., Qin, B., Cai, X., Wu, M., Li, J., Wang, J.: Diabetic kidney disease: from pathogenesis to multimodal therapy–current evidence and future directions. Front. Med. 12, (2025). https://doi.org/10.3389/fmed.2025.1631053

CITE AS: Mpora Kakwanzi Evelyn (2026). Hepatic Glucokinase Activators versus Sulfonylureas: Hypoglycemia Risk Reduction in Type 2 Diabetes Management. RESEARCH INVENTION JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES 6(1):38-42. https://doi.org/10.59298/RIJBAS/2026/613842